Higher Dose and Dose-Rate in Smaller Tumors Result in Improved Tumor Control

References

• Boyle P. Some recent developments in the epidemiology of colorectal cancer. Management of colorectal cancer, H. Bleiberg, P. Rougier, H.J. Wilke. Martin Dunitz, London 1998; 19–34
   Google Scholar
• Moertel C.G., Fleming T.R., MacDonald J.S., Haller D.G., Laurie J.A., Goodman P.J., Ungerleider J.S., Emerson W.A., Tormey D.C., Glick J.H., Veeder M.H., Mailliard J.A. Levamisol and fluorouracil for adjuvant therapy of resected colon carcinoma. NEJM 1990; 322: 352–358
   PubMed Web of Science ®Google Scholar
• Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEJM 2001; 344(11)783–792
   PubMed Web of Science ®Google Scholar
• Maloney D.G., Liles T.M., Czerwinski D.K., Waldichuk C., Rosenberg J., Grillo-Lopez A., Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84(8)2457–2466
   PubMed Web of Science ®Google Scholar
• Riethmuller G., Holz E., Schlimok G., Schmiegel W., Raab R., Hoffken K., Gruber R., Funke I., Pichlmaier H., Hirche H., Buggisch P., Witte J., Pichlmayr R. Monoclonal antibody therapy for resected Duke's C colorectal cancer: Seven year outcome of a randomised controled trial. J. Clin. Oncol. 1998; 16: 1788–1794
   PubMed Web of Science ®Google Scholar
• Punt C.J., Nagy A., Douillard J., Figer A., Skovsgaard T., Monson J., Barone C., Jones D., Dethling J., Colman J. Edrecolomab (17-1A antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a phase III study. ASCO Proc 2001; 20: 123a, 487
   Google Scholar
• Lane D.M., Eagle K.F., Begent R.H., Hope-Stone L.D., Green A.J., Casey J.L., Keep P.A., Kelly A.M., Ledermann J.A., Glaser M.G., Hilson A.J.W. Radioimmunotherapy of metastatic colorectal tumours with iodine 131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br. J. Cancer 1994; 70: 521–525
   PubMed Web of Science ®Google Scholar
• Behr T.M., Liersch T., Canelo R., Woermann B., Hiddemann W., Ringe B., Becker H., Becker W. Radioimmunotherapy of small volume disease of colorectal cancer: results of a clinical Phase I/II trial. EJC 1999; 35(Suppl. 5)93
   Google Scholar
• Pedley R.B., Boden J., Keep P.A., Harwood P.J., Green A.J., Rogers G.T. Relationship between tumour size and uptake of radiolabelled anti-CEA in a colon tumour xenograft. Eur. J. Nucl. Med. 1987; 13: 197–202
   PubMedGoogle Scholar
• Blumenthal R.D., Sharkey R.M., Haywood L., Natale A.M., Wong G.Y., Siegel J.A., Kennel S.J., Goldenberg D.M. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Cancer Res. 1992; 52: 6036–6044
   PubMed Web of Science ®Google Scholar
• Flynn A.A., Green A.J., Boxer G.M., Casey J.L., Pedley R.B., Begent R.H.J. A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model. Int. J. Rad. Onc. Biol. Phys. 1999; 43: 183–189
   PubMed Web of Science ®Google Scholar
• Yokota T., Milencic D.E., Whitlow M., Schlom J. Rapid tumour penetration of a single chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992; 52: 1402–1408
   Google Scholar
• Krol A., Maresca J., Dewhirst M.W., Yuan F. Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: Implications for drug delivery. Cancer Res. 1999; 59: 4136–4141
   PubMed Web of Science ®Google Scholar
• Blumenthal R.D., Sharkey R.M., Natale A.M., Kashi R., Wong G., Goldenberg D.M. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic xenografts. Cancer Res. 1994; 54: 142–151
   PubMed Web of Science ®Google Scholar
• Mayer A., Chester K.A., Bhatia J., Pedley R.B., Read D.A., Boxer G.M., Begent R.H. Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibody. Eur. J. Cancer 1998; 34: 968–976
   PubMed Web of Science ®Google Scholar
• Laroche S. Managing very large-scale digital images in microscopy. Microscopy and Analysis 1998; 7: 5–7
   Google Scholar
• Flynn A.A., Green A.J., Boxer G., Pedley R.B., Begent R.H.J. A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology. Phys. Med. Biol. 1999; 44: 151–159
   Google Scholar
• Bardies M., Chatal J.-F. Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres. Phys. Med. Biol. 1994; 39: 961–981
   PubMed Web of Science ®Google Scholar
• Berger M.J. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. Society of Nuclear Medicine, New York 1971
   Google Scholar
• Jain R.K. Haemodynamic and transport barriers to the treatment of solid tumours. Int. J. Radiat. Biol. 1991; 60: 85–100
   PubMed Web of Science ®Google Scholar
• Dvorak H.F., Nagy J.A., Dvorak J.T., Dvorak A.M. Identification and characterization of the blood vessels of solid tumours that are leaky to circulating macromolecules. Am. J. Pathol. 1988; 133: 95–109
   PubMed Web of Science ®Google Scholar
• Blumenthal R.D., Kashi R., Sharkey R.M., Goldenberg D.M. Quantitative and qualitative effects of experimental radioimmunotherapy on tumour vascular permeability. Int. J. Cancer 1995; 61: 557–566
   PubMed Web of Science ®Google Scholar